	US 12,360,108 B2
	Biotin-specific monoclonal antibody and use thereof
Michael Gerg, Munich (DE); Klaus Hirzel, Baierbrunn (DE); Caroline Hojer, Munich (DE); Erasmus Huber, Finning (DE); Hans-Peter Josel, Weilheim (DE); Thomas Meier, Munich (DE); Michael Schraeml, Penzberg (DE); and Leopold Von Proff, Hohenpeissenberg (DE)
Assigned to Roche Diagnostics Operations, Inc.
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Dec. 15, 2021, as Appl. No. 17/551,716.
Application 17/551,716 is a division of application No. 16/450,176, filed on Jun. 24, 2019, abandoned.
Application 16/450,176 is a continuation of application No. PCT/EP2017/083572, filed on Dec. 19, 2017.
Claims priority of application No. 16206944 (EP), filed on Dec. 27, 2016; and application No. 17184142 (EP), filed on Jul. 31, 2017.
Prior Publication US 2022/0107309 A1, Apr. 7, 2022
Int. Cl. G01N 33/543 (2006.01); C07K 16/44 (2006.01)

CPC G01N 33/54306 (2013.01) [C07K 16/44 (2013.01)]

2 Claims

1. An immunogen according to Formula I:

OG Complex Work Unit Chemistry

wherein:

R is Z-L,

L-X-Y together are suberyl-beta-alanyl, and

Z is a polypeptide of at least 30 amino acids.